Anti-ROR1 Antibody (Zilovertamab): Specificity & Integration Guide

Executive Summary: Anti-ROR1 Antibody (Zilovertamab), offered by APExBIO, is a humanized IgG1 monoclonal antibody produced in CHO cells and purified to >95% purity for research use (product_spec). It specifically binds to human ROR1 and blocks Wnt5a-induced ROR1 signaling implicated in tumor progression (product_spec). The antibody is unconjugated and supplied in a stabilizing buffer at pH 5.0, optimized for ELISA, FACS, kinetic, and animal model assays. Proper storage at -80°C and avoiding freeze-thaw cycles preserves activity. Validation data confirm functional specificity and high-affinity binding at 2 µg/mL to immobilized human ROR1 (product_spec).

Biological Rationale

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a transmembrane protein involved in Wnt5a-induced noncanonical Wnt signaling. Aberrant ROR1 expression is associated with various malignancies, including chronic lymphocytic leukemia and solid tumors (DOI). Targeting ROR1 has emerged as a promising strategy for cancer therapy due to its restricted expression in adult tissues and high prevalence in tumors. Inhibition of ROR1 disrupts essential pathways in tumor cell proliferation and survival, making it a critical focus for antibody-based therapeutics. Zilovertamab, a humanized monoclonal antibody, is designed to bind ROR1 with high specificity, thereby interfering with oncogenic signaling cascades. For a detailed exploration of workflow optimization in cancer models, see Applied Workflows for Anti-ROR1 Antibody (Zilovertamab) in Cancer Research, which this article extends by emphasizing molecular specificity and integration parameters.

Mechanism of Action of Anti-ROR1 Antibody (Zilovertamab)

Zilovertamab functions by specifically binding to the extracellular domain of human ROR1, preventing Wnt5a ligand engagement. This blockade inhibits downstream noncanonical Wnt signaling, curtailing tumor cell migration and proliferation. In vitro, Anti-ROR1 Antibody (Zilovertamab) demonstrates high-affinity binding to immobilized ROR1 at concentrations as low as 2 µg/mL (product_spec). The antibody is produced in Chinese hamster ovary (CHO) cells and purified by Protein A chromatography, ensuring a molecular weight of approximately 145.12 kDa and a purity greater than 95% (as confirmed by both SDS-PAGE and SEC-HPLC) (product_spec).

Evidence & Benchmarks

• Anti-ROR1 Antibody (Zilovertamab) binds human ROR1 His-tagged protein at 2 µg/mL, confirming specificity (source: product_spec).
• Purity exceeds 95% as validated by both SDS-PAGE and SEC-HPLC (source: product_spec).
• Supplied as a liquid formulation in 100 mM proline, 20 mM arginine, pH 5.0 buffer with no preservatives (source: product_spec).
• Storage at -80°C is recommended to maintain stability and biological activity; repeated freeze-thaw cycles should be avoided (source: product_spec).
• Validated for ELISA, FACS, functional assays, kinetic studies, and in vivo animal models (source: product_spec).

For guidelines on assay performance and troubleshooting, Anti-ROR1 Antibody (Zilovertamab): Applied Cancer Research Workflows provides practical extensions to this article by focusing on reproducibility and assay setup.

Applications, Limits & Misconceptions

Anti-ROR1 Antibody (Zilovertamab) is validated for use in ELISA, FACS, kinetic binding assays, functional cell-based assays, and animal models. Its high specificity makes it suitable for mechanistic studies of Wnt5a-induced ROR1 signaling inhibition and for evaluating anti-tumor antibody responses. However, its unconjugated format limits direct detection in some multiplexed assays unless further labeled. The antibody is not indicated for therapeutic use in humans and should not be used as a diagnostic reagent. Comparative studies have shown that ROR1 targeting is highly selective for tumor models expressing ROR1, and off-target effects are minimal under recommended conditions (product_spec). For a broader mechanistic context, see Deoxynivalenol Liver Injury: Role of Mitophagy and Nrf2 Pathways, which this article clarifies by distinguishing ROR1-targeted anti-tumor strategies from hepatotoxicity models reliant on different signaling axes.

Common Pitfalls or Misconceptions

• Using the antibody in diagnostic or therapeutic clinical applications—current validation is limited to research use only (product_spec).
• Assuming cross-reactivity with non-human or non-ROR1 targets—the antibody's epitope mapping confirms specificity for human ROR1 (product_spec).
• Vortexing during reconstitution—gentle mixing is required to preserve protein integrity (workflow_recommendation).
• Expecting efficacy in ROR1-negative models—the antibody only acts on ROR1-expressing cells/tissues (workflow_recommendation).
• Repeated freeze-thaw cycles—these will reduce binding activity due to protein denaturation (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• ELISA | 2 µg/mL | Human ROR1-coated plates | Confirm specificity and dynamic range | product_spec
• FACS | 1–10 µg/mL | ROR1+ cell lines | Assess surface expression of ROR1 | workflow_recommendation
• Functional assay | 1–5 µg/mL | ROR1+ tumor models | Evaluate inhibition of Wnt5a-induced signaling | workflow_recommendation
• Kinetic binding | 2 µg/mL | Recombinant ROR1 | Determine affinity and binding kinetics | product_spec
• Animal model | 2–10 mg/kg | ROR1+ xenograft models | Assess in vivo anti-tumor effect | workflow_recommendation
• Storage | -80°C | All formats | Preserve biological activity | product_spec
• Buffer | 100 mM proline, 20 mM arginine, pH 5.0 | All applications | Protein stability | product_spec

For in-depth integration strategies and troubleshooting in translational workflows, Applied Cancer Research with Anti-ROR1 Antibody (Zilovertamab) updates prior protocols by offering stepwise optimization for animal models and cell-based assays.

Conclusion & Outlook

Anti-ROR1 Antibody (Zilovertamab) from APExBIO represents a rigorously validated research reagent for specific inhibition of Wnt5a-induced ROR1 signaling in cancer models. Its high purity, stability, and binding specificity support reproducible results in ELISA, FACS, and functional studies. Future work will likely focus on refining workflow integration and expanding in vivo applications within the research context. The evidence base demonstrates reliable performance when employed as directed, but therapeutic or diagnostic use remains outside current validation scope. For optimized workflows and new mechanistic insights, consult referenced guides and product documentation.